Enna Dogra Gupta1, Gaurav Anand1, Hina Singh1, Kritika Chaddha2, Praveen K Bharti3, Neeru Singh3, Yagya Dutta Sharma4, Deepak Gaur1,2. 1. Malaria Group, International Centre for Genetic Engineering and Biotechnology. 2. Laboratory of Malaria & Vaccine Research, School of Biotechnology, Jawaharlal Nehru University, and. 3. National Institute for Research in Tribal Health, Jabalpur, Madhya Pradesh, India. 4. Department of Biotechnology, All India Institute of Medical Sciences, New Delhi, and.
Abstract
Background: Crucial gaps in our understanding of Plasmodium vivax reticulocyte invasion and protective immunity have hampered development of vivax vaccines. P. vivax exclusively invades reticulocytes that is mediated by the P. vivax reticulocyte-binding proteins (PvRBPs) specifically PvRBP2c and PvRBP1a. Vivax infections in Duffy-null individuals have suggested the evolution of alternate invasion pathways that may be mediated by the PvRBPs. Thus, PvRBPs appear as potential targets for efficacious P. vivax neutralization. However, there are limited data validating their vaccine efficacy. In the absence of vivax invasion assays, binding-inhibitory activity of antibodies has been reported to be associated with protection and a measure of vaccine potential. Methods: -based analysis was performed of the PvRBP reticulocyte-binding properties and binding-inhibitory activity of specific anti-PvRBP2c/PvRBP1a human antibodies. Results: PvRBP2c and PvRBP1a displayed a distinct reticulocyte-binding specificity, and their specific reticulocyte-binding domains were mapped within their N-terminal regions. Importantly, naturally acquired antibodies against the reticulocyte-binding domains efficaciously blocked reticulocyte binding of native PvRBPs, suggesting that the human immune system produced functional binding-inhibitory antibodies through exposure to vivax malaria. Conclusions: Reticulocyte-binding domains of PvRBP2c/PvRBP1a are targets of naturally acquired binding-inhibitory antibodies, substantiating their promise as candidate antigens against which vaccine-inducible immunity could potentially be boosted through natural infections.
Background: Crucial gaps in our understanding of Plasmodium vivax reticulocyte invasion and protective immunity have hampered development of vivax vaccines. P. vivax exclusively invades reticulocytes that is mediated by the P. vivax reticulocyte-binding proteins (PvRBPs) specifically PvRBP2c and PvRBP1a. Vivax infections in Duffy-null individuals have suggested the evolution of alternate invasion pathways that may be mediated by the PvRBPs. Thus, PvRBPs appear as potential targets for efficacious P. vivax neutralization. However, there are limited data validating their vaccine efficacy. In the absence of vivax invasion assays, binding-inhibitory activity of antibodies has been reported to be associated with protection and a measure of vaccine potential. Methods: -based analysis was performed of the PvRBP reticulocyte-binding properties and binding-inhibitory activity of specific anti-PvRBP2c/PvRBP1a human antibodies. Results: PvRBP2c and PvRBP1a displayed a distinct reticulocyte-binding specificity, and their specific reticulocyte-binding domains were mapped within their N-terminal regions. Importantly, naturally acquired antibodies against the reticulocyte-binding domains efficaciously blocked reticulocyte binding of native PvRBPs, suggesting that the human immune system produced functional binding-inhibitory antibodies through exposure to vivax malaria. Conclusions: Reticulocyte-binding domains of PvRBP2c/PvRBP1a are targets of naturally acquired binding-inhibitory antibodies, substantiating their promise as candidate antigens against which vaccine-inducible immunity could potentially be boosted through natural infections.
Authors: Didier Ménard; Céline Barnadas; Christiane Bouchier; Cara Henry-Halldin; Laurie R Gray; Arsène Ratsimbasoa; Vincent Thonier; Jean-François Carod; Olivier Domarle; Yves Colin; Olivier Bertrand; Julien Picot; Christopher L King; Brian T Grimberg; Odile Mercereau-Puijalon; Peter A Zimmerman Journal: Proc Natl Acad Sci U S A Date: 2010-03-15 Impact factor: 11.205
Authors: G S Tanwar; P C Khatri; G S Sengar; A Kochar; S K Kochar; S Middha; G Tanwar; N Khatri; D Pakalapati; S Garg; A Das; D K Kochar Journal: Ann Trop Paediatr Date: 2011
Authors: Karthigayan Gunalan; Eugenia Lo; Jessica B Hostetler; Delenasaw Yewhalaw; Jianbing Mu; Daniel E Neafsey; Guiyun Yan; Louis H Miller Journal: Proc Natl Acad Sci U S A Date: 2016-05-17 Impact factor: 11.205
Authors: Peter W Gething; Iqbal R F Elyazar; Catherine L Moyes; David L Smith; Katherine E Battle; Carlos A Guerra; Anand P Patil; Andrew J Tatem; Rosalind E Howes; Monica F Myers; Dylan B George; Peter Horby; Heiman F L Wertheim; Ric N Price; Ivo Müeller; J Kevin Baird; Simon I Hay Journal: PLoS Negl Trop Dis Date: 2012-09-06
Authors: Linda Reiling; Jack S Richards; Freya J I Fowkes; Danny W Wilson; Watcharee Chokejindachai; Alyssa E Barry; Wai-Hong Tham; Janine Stubbs; Christine Langer; John Donelson; Pascal Michon; Livingstone Tavul; Brendan S Crabb; Peter M Siba; Alan F Cowman; Ivo Mueller; James G Beeson Journal: PLoS One Date: 2012-09-20 Impact factor: 3.240
Authors: Tarcisio A A Carvalho; Maíse G Queiroz; Greice L Cardoso; Isabela G Diniz; Aylla N L M Silva; Ana Y N Pinto; João F Guerreiro Journal: Malar J Date: 2012-12-22 Impact factor: 2.979
Authors: Francis B Ntumngia; Richard Thomson-Luque; Sandra Galusic; Gabriel Frato; Sarah Frischmann; David S Peabody; Bryce Chackerian; Marcelo U Ferreira; Christopher L King; John H Adams Journal: J Infect Dis Date: 2018-08-24 Impact factor: 5.226
Authors: Wen-Qiang He; Stephan Karl; Michael T White; Wang Nguitragool; Wuelton Monteiro; Andrea Kuehn; Jakub Gruszczyk; Camila T França; Jetsumon Sattabongkot; Marcus V G Lacerda; Wai-Hong Tham; Ivo Mueller Journal: PLoS Negl Trop Dis Date: 2019-08-19